Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization time 30% Improvement Relative Risk c19early.org/z Alahmari et al. Zinc for COVID-19 LATE TREATMENT Is late treatment with zinc beneficial for COVID-19? Retrospective 977 patients in Saudi Arabia (May - July 2020) Shorter hospitalization with zinc (p<0.000001) Alahmari et al., Healthcare, doi:10.3390/healthcare10071201 Favors zinc Favors control
Factors Associated with Length of Hospital Stay among COVID-19 Patients in Saudi Arabia: A Retrospective Study during the First Pandemic Wave
Alahmari et al., Healthcare, doi:10.3390/healthcare10071201
Alahmari et al., Factors Associated with Length of Hospital Stay among COVID-19 Patients in Saudi Arabia: A Retrospective Study.., Healthcare, doi:10.3390/healthcare10071201
Jun 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 977 hospitalized patients in Saudi Arabia, showing significantly shorter hospitalization with zinc treatment.
hospitalization time, 30.2% lower, relative time 0.70, p < 0.001, treatment mean 6.39 (±0.76) n=130, control mean 9.15 (±0.27) n=847.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alahmari et al., 27 Jun 2022, retrospective, Saudi Arabia, peer-reviewed, 7 authors, study period 1 May, 2020 - 30 July, 2020.
Contact: a.alahmari@psau.edu.sa (corresponding author), z.almalki@psau.edu.sa, aa.albassam@psau.edu.sa, ah.alshehri@psau.edu.sa, n.ahmed@psau.edu.sa, mmaalsultan@iau.edu.sa, ph.abdalhadi@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperZincAll
Abstract: healthcare Article Factors Associated with Length of Hospital Stay among COVID-19 Patients in Saudi Arabia: A Retrospective Study during the First Pandemic Wave Abdullah K. Alahmari 1, * , Ziyad S. Almalki 1 , Ahmed A. Albassam 1 , Mohammed M. Alsultan 2 , Ahmed M. Alshehri 1 , Nehad J. Ahmed 1 and Abdulhadi M. Alqahtani 3 1 2 3 * Citation: Alahmari, A.K.; Almalki, Z.S.; Albassam, A.A.; Alsultan, M.M.; Alshehri, A.M.; Ahmed, N.J.; Alqahtani, A.M. Factors Associated with Length of Hospital Stay among COVID-19 Patients in Saudi Arabia: A Retrospective Study during the First Pandemic Wave. Healthcare 2022, 10, 1201. https:// doi.org/10.3390/healthcare10071201 Academic Editors: Giuseppe Di Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia; z.almalki@psau.edu.sa (Z.S.A.); aa.albassam@psau.edu.sa (A.A.A.); ah.alshehri@psau.edu.sa (A.M.A.); n.ahmed@psau.edu.sa (N.J.A.) Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia; mmaalsultan@iau.edu.sa Clinical Research Department, Research Center, King Fahad Medical City, Riyadh 12231, Saudi Arabia; ph.abdalhadi@gmail.com Correspondence: a.alahmari@psau.edu.sa Abstract: The COVID-19 pandemic severely affected healthcare systems and tested their preparedness. To date, the length of hospital stay (LoHS) and its factors among COVID-19 patients has not been thoroughly studied. Moreover, it is essential to identify the features of these patients. Adult COVID-19 patients in Saudi Arabia with complete electronic medical records and who were hospitalised for >1 day between 1 May 2020 and 30 July 2020 at one of two hospitals were considered for this retrospective cohort study. Descriptive statistics and multivariate generalized linear models were performed using the data. Of the patients, 34% were ≥50 years old and 80.14% were female. More than 70% had mild-to-moderate symptoms; 45% had either diabetes or hypertension. The median LoHS was 7.00 days (IQR: 3–11). Patients who were females, had either critical or severe disease, were on mechanical ventilation, had diabetes, and administered ceftriaxone had significantly longer LoHS (p < 0.05). Patients administered zinc sulphate had significantly shorter LoHS (p = 0.0008). During the first pandemic wave, COVID-19 patients were hospitalised for 7 days. Healthcare professionals should pay more attention to women, patients with diabetes, and those with severe or critical symptoms. Unnecessary use of ceftriaxone should be minimised, and zinc sulphate can be administered. Martino, Tommaso Staniscia, Fabrizio Cedrone and Mustafa Z. Younis Keywords: COVID-19; hospital stay; hospitalisation; health systems Received: 8 April 2022 Accepted: 21 June 2022 Published: 27 June 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit